Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mogamulizumab for ATL prevention in high-risk HTLV-1 carriers
NCT06698003Phase 2Recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Nov 2024
- Primary completion
- Nov 2029
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of mogamulizumab in adult T-cell leukemia-lymphoma (ATLL), sponsored by Memorial Sloan Kettering Cancer Center. Started Nov 2024; status: recruiting.
02
Drugs
mogamulizumab
03
Conditions
adult T-cell leukemia-lymphoma (ATLL)
Beyond the preview
Go deeper on NCT06698003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06698003.